Mannkind (MNKD) Gains from Investment Securities (2016 - 2025)
Mannkind's (MNKD) quarterly Gains from Investment Securities came in at $1.0 million in Q4 2025, down 59.0% on a QoQ basis from $2.5 million in Q4 2016.
Mannkind (MNKD) Gains from Investment Securities (2016 - 2025) Analysis & Trends
Mannkind (MNKD) has 2 years of Gains from Investment Securities data on file, last reported at $1.0 million in Q4 2025.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $1.0 million in Q4 2025; TTM through Dec 2025 was $19.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.0 million, changed N/A from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $1.0 million, down from $2.5 million in the prior quarter.
- Over the last five years, Gains from Investment Securities for MNKD reached as high as $1.0 million in Q4 2025 and fell as low as $1.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - |
| 2 | Nanobiotix | 1,924.26 Bn | 1,924.20 Bn | - |
| 3 | Akari Therapeutics | 975.59 Bn | 975.59 Bn | - |
| 4 | BeOne Medicines | 472.11 Bn | 467.32 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.89 Bn | 114.65 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.83 Bn | 62.83 Bn | - |
| 8 | Argenx Se | 55.82 Bn | 50.63 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.49 Bn | 37.49 Bn | - |
| 10 | Mannkind | 1.25 Bn | 1.12 Bn | 82.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.03 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Dec 31, 2016 | 2.51 Mn |
| Dec 31, 2016 | 2.51 Mn |
| Sep 30, 2016 | 13.20 Mn |
| Sep 30, 2016 | 13.20 Mn |
| Jun 30, 2016 | 2.40 Mn |
| Jun 30, 2016 | 2.40 Mn |
| Mar 31, 2016 | 2.36 Mn |
| Mar 31, 2016 | 2.36 Mn |